Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1

Conditions

Wilms Tumor 1Multiple Myeloma 1Hematologic Neoplasms 1

Interventions

Vincristine 2sargramostim 1regorafenib 1racotumomab 1pembrolizumab 1entrectinib 1Proteasome Inhibitors 1Nivolumab 1Monatide (IMS 3015) 1Lenalidomide 1Irinotecan 1Immunomodulating Agents 1Granulocyte-Macrophage Colony-Stimulating Factor 1CLR1404 1Bortezomib 1Biological Factors 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Wilms Tumor × Immunomodulating Agents × Clear all
NCT01827137 2024-09-19

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

Sellas Life Sciences Group

Phase 1/2 Completed
20 enrolled 9 charts
GenitourinaryPlasma cell

Multiple Myeloma, Wilms Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡